Federal Appeals Court Reinstates Oregon Drug Price Transparency Law After PhRMA Challenge
核心洞察
The 9th Circuit Court of Appeals (搜索) reversed a lower court ruling in a 2-1 decision, reinstating Oregon's House Bill 4005 that requires pharmaceutical manufacturers to report pricing information on drugs costing over $100 monthly.
PhRMA (搜索) challenged the law claiming it violated First and Fifth Amendment rights by compelling disclosure of trade secrets, but the appeals court found the reporting requirements directly advance the state's goal of reducing information asymmetries in pharmaceutical markets.
The 2024 suspension of the law led to a 94% drop in price increase reporting from pharmaceutical companies, preventing meaningful transparency analysis that had previously tracked hundreds of drug reports since 2019.
The 9th Circuit Court of Appeals (搜索) delivered a significant victory for drug price transparency advocates Tuesday, reversing a lower court decision that had suspended Oregon's pharmaceutical reporting requirements following a constitutional challenge by the industry's leading trade group.
In a 2-1 decision, the federal appeals court reinstated Oregon's House Bill 4005, a 2018 law requiring prescription drug manufacturers to submit annual price reports on medications costing more than $100 for a month's supply. The ruling reversed U.S. District Court Judge Michael Mosman's February 2024 decision that had sided with the Pharmaceutical Research and Manufacturers of America (搜索) (PhRMA (搜索)) in suspending key provisions of the transparency law.
Constitutional Challenge and Industry Opposition
PhRMA (搜索) had argued that Oregon's reporting requirements violated both First and Fifth Amendment protections by compelling manufacturers to disclose sensitive competitive information and effectively confess responsibility for price increases. The trade group contended the law forced companies to reveal trade secrets without compensation, constituting an unconstitutional taking of property.
"The lower court correctly found that forcing manufacturers to disclose trade secrets without compensation is unconstitutional and compelling companies to speak on a controversial topic violates the First Amendment," said Reid Porter, a PhRMA (搜索) spokesperson, in response to the appeals court decision.
The original district court ruling had found that "Oregon has not identified studies or evidence to show how the reporting requirements of HB 4005 will directly advance its legislative goals," according to Judge Mosman's 2024 opinion.
Appeals Court Rationale
Circuit Judge Lucy Koh, who authored the appeals court opinion, rejected PhRMA (搜索)'s constitutional arguments and found merit in Oregon's transparency approach. The court distinguished between directly lowering drug prices and the state's actual legislative goal of market transparency.
"The state has never claimed that HB 4005's reporting requirement itself will directly lower drug prices. Rather, the state's stated goal in enacting HB 4005 was to reduce information asymmetries in the pharmaceutical market and provide drug purchasers with leverage in negotiations with manufacturers," the ruling stated.
The court emphasized the logical connection between information gathering and market transparency: "It is common sense that collecting and publishing information about drug pricing costs and pharmaceutical market conditions directly advances this goal."
Broad State Support and Implementation Impact
The case attracted significant attention from state governments nationwide, with 21 state attorneys general filing an amicus brief supporting Oregon's position. These states sought to defend the precedent for their own existing or planned drug price transparency legislation.
Under the law, the Oregon Department of Consumer and Business Services (搜索) requires pharmaceutical companies to provide "a narrative description and explanation of all major financial and nonfinancial factors" surrounding drug price increases, with penalties ranging up to $10,000 in daily fines for non-compliance.
Dramatic Decline in Transparency During Suspension
The suspension's impact on drug price monitoring was severe and immediate. State analysts documented a 94% drop in price increase reporting from pharmaceutical companies in 2024 compared to previous years when the law was fully operational.
Since 2019, the consumer services department had fielded hundreds of required reports covering various therapeutic categories. The agency's 2023 report identified blood thinners (搜索), antivirals (搜索), steroid hormones (搜索) for pain and inflammation, opioids (搜索), and cancer treatments (搜索) among the most commonly reported drugs requiring price justification.
"With such a small amount of limited data collected, the program cannot provide meaningful transparency or analysis as it has in prior years," state analysts wrote in their 2024 assessment.
The suspension prevented the state from providing public information comparing generic and brand name drugs, analyzing drug prices relative to inflation, and tracking broader pricing trends over time.
Legislative and Regulatory Response
State Rep. Rob Nosse, D-Portland, one of the lead sponsors of House Bill 4005, expressed enthusiasm about the ruling's potential to restart transparency efforts. "I was thrilled with the ruling and hopeful the state could begin to track the disputed factors driving up prices yet again," he told the Capital Chronicle.
Oregon Attorney General Dan Rayfield framed the decision as a victory for consumers facing rising healthcare costs. "The cost of living — including prescription drug prices — continues to climb. This ruling ensures we all have transparency into the prices we pay at the pharmacy, and it's a significant win for Oregonians," he stated.
However, the Oregon Department of Consumer and Business Services (搜索) indicated the legal battle may continue. "While there has been a judgement in the case, it is not a final disposition — technically this means the litigation is still ongoing," said Numi Lee Griffith, a senior policy advisor for the agency.
PhRMA (搜索) indicated it was "reviewing the decision and evaluating next steps," suggesting potential further legal challenges to the transparency requirements.